iCMLf International Chronic Myeloid Leukemia Foundation

ESH EUROPEAN SCHOOL OF HAEMATOLOGY

27th Annual John Goldman Conference on CHRONIC MYELOID LEUKEMIA: BIOLOGY AND THERAPY

October 10-12, 2025 – Estoril, Portugal

Chairs: J. Cortes, T.P. Hughes, D.S. Krause

Co-Organizers: R. Bhatia, T. Brümmendorf, M. Copland, M. Deininger, O. Hantschel, V. Helgason, S. T. Ong, J. Radich, D. Réa

Advisory Committee: J. Apperley, S. Branford, C. Gambacorti-Passerini, F. Guilhot, R. Hehlmann, P. Laneuville, F-X. Mahon, D. Perrotti, G. Saglio, C. Schiffer, S. Soverini, P. Valent, R. Van Etten

Friday, October 10, 2025

08:00-08:05	**Welcome**	Jorge Cortes (Augusta)
08:05-08:10	**Welcome to Estoril**	António Almeida (Lisbon)
08:10-08:20	**iCMLf - A review**	Jorge Cortes (Augusta)

SCIENTIFIC SESSION 1: TOP SCORING ABSTRACTS 2025 *(12' + 3' discussion)*
Chairs: Daniele Sarnello (Glasgow), Kendra Sweet (Tampa)

08:20-08:35	Early response prediction by single-cell immune and signaling profiling in chronic myeloid leukemia	Stein-Erik Gullaksen (Bergen)
08:35-08:50	ENABLE: a phase 1 study of ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with previously treated CML	Fabian Lang (Frankfurt)
08:50-09:05	Next generation sequencing from dried blood spots in low- and middle-income countries: "Spot on CML" results	Vivian Oehler (Seattle)
09:05-09:20	Tyrosine kinase inhibition alters macrophage polarization in chronic myeloid leukemia to regulate leukemic stem cell potential	Tiffany Ricketts (Birmingham, USA)
09:20-09:35	Asciminib shows superior tolerability vs Nilotinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): results from the phase 3b, randomized, open-label, ASC4START trial	François-Xavier Mahon (Bordeaux)
09:35-09:50	Detailed molecular insight into resistance mechanisms of the allosteric BCR::ABL1 inhibitor asciminib	Inga B. Leske (Marburg)
09:50-10:05	Mutually dependent leukaemia stem cell states govern lineage trajectories that reflect clinical outcomes in chronic phase CML	Mary Scott (Glasgow)

10:05-10:35 Coffee Break

TESSA HOLYOAKE MEMORIAL LECTURE: SPECIAL LECTURE (1) *(20' + 5' discussion)*
Chair: Daniela Krause (Mainz)

10:35-10:55	Extrinsic and intrinsic interferon signaling in healthy and malignant stem cells	Marieke Essers (Heidelberg)
10:55-11:00	*Discussion*	

SCIENTIFIC SESSION 2: Stem Cells
Chair: Mary Scott (Glasgow)

11:00-11:15	**Keynote Presentation:** Inflammation and CML stem cells: the devil is in the details	David Vetrie (Glasgow)
11:15-11:20	*Discussion*	
	Selected Abstracts: *(12' + 3' discussion)*	
11:20 -11:35	Identification of leukemic stem cells of chronic myeloid leukemia in a new mouse model	Yasmine Pobiedonoscew (Bordeaux)
11:35-11:50	Exploring the role of megakaryocytes in leukemic stem cell persistence	Margherita Vieri (Aachen)
11:50-12:05	A potential role for IGFBP2 in regulating the CML stem cell niche	Henrike Jacobi (Aachen)
12:05-12:15	**JANET ROWLEY PRIZE PRESENTATION** **Presenter:** Andreas Hochhaus (Jena) **Awardee 2025:** Satu Mustjoki (Helsinki)	

JANET ROWLEY PRIZE: SPECIAL LECTURE (2)
Chair: Andreas Hochhaus (Jena)

12:15-12:35	CML immunology: The journey from bone marrow lymphocytosis to NK cell function	Satu Mustjoki (Helsinki)
12:35-12:40	*Discussion*	

12:40-14:40 Lunch and Poster Viewing

13:30-14:30 **SATELLITE SYMPOSIUM**
Balancing tolerability and efficacy in CML:
strategies to improve long-term outcomes in the newly diagnosed setting
Chair: António Almeida (Lisbon)
Speakers: António Almeida (Lisbon), Jane F. Apperley (London), Tim Brümmendorf (Aachen)

This symposium is organized and sponsored by Novartis

SPECIAL LECTURE (3):
Chair: Mirle Schemionek (Aachen)

14:40-15:00	Evolutionary therapy for metastatic cancer	Alexander Anderson (Tampa)
15:00-15:05	*Discussion*	

SCIENTIFIC SESSION 3: Cell biology
Chair: Oliver Hantschel (Marburg)

15:05-15:20	**Keynote Presentation:** A single-cell chromatin accessibility atlas reveals transcription factor-driven epigenetic programmes underlying drug resistance and blast crisis progression in CML	Sin Tiong Ong (Singapore)
15:20-15:25	*Discussion*	
	Selected Abstracts: *(12' + 3' discussion)*	
15:25-15:40	A coordinated stress-adaptive response underlies the tumor suppressor role of G0S2 in CML	Briandy Fernandez-Marrero (El Paso)
15:40-15:55	Integrating genomic and transcriptomic features for predicting responses and outcomes in chronic myeloid leukemia on third-generation TKI therapy	Xiaoshuai Zhang (Beijing)
15:55-16:10	Complex metabolic reprogramming underlies TKI resistance in CML stem progenitor cells	Ilaria Stefania Pagani (Adelaide)
16:10-16:40	***Coffee Break***	

MICHELE BACCARANI SPECIAL SYMPOSIUM *(12' + 5' discussion)*
Chair: Michael Deininger (Ann Arbor), Rüdiger Hehlmann (Weinheim)

16:40-16:50	Introduction	
16:50-17:07	Lessons learned from fibrosis in MPN and beyond	Gerlinde Wernig (Stanford)
17:07-17:24	Targeting Mutated Calreticulins in Myeloproliferative Neoplasms and Secondary Acute Myeloid Leukemia	Stefan Constantinescu (Brussels)
17:24-17:41	New developments in the treatment of Myelofibrosis, the future of Myeloproliferative disorders with focus on combinations	John Mascarenhas (New York)
17:41-17:58	Exploring new biomarkers in MPN	David Ross (Adelaide)
17:58-18:28	General Discussion	

18:35-19:35 **Poster Session 1 and Welcome Get-Together**
Poster leaders: Anna Eiring (El Paso), Emre Eşkazan (Istanbul), Hemant Malhotra (Jaipur)

Saturday, October 11, 2025

WORKSHOP FOR NON-CLINICAL SCIENTISTS #1: Mitochondria biology - Metabolism and other aspects of Mitochondria
Chairs: Vignir Helgason (Glasgow), Sin Tiong Ong (Singapore)

07:40-07:45	Introduction	
07:45-08:10	Illuminating mitochondrial autophagy	Ian Ganley (Dundee)
08:10-08:20	*Discussion*	
08:20-08:45	Mitochondrial DNA mutations in cancer: prevalent and relevant - *EMBO Young Investigator Lecture* -	Payam Gammage (Glasgow)
08:45-08:55	*Discussion*	
08:55-09:20	Targeting mitochondrial metabolism to rescue hematopoietic stem cell function	Els Mansell (Rotterdam)
09:20-09:30	*Discussion*	
09:30-09:40	Conclusion	

08:55-09:55 **CONCURRENT MEET-THE-EXPERT SESSIONS (pre-registration required)**
1. Pregnancy – Jane Apperley (London) and Ekaterina Chelysheva (Moscow)
2. Dosing of the TKIs – Daniela Žáčková (Brno) and Mhairi Copland (Glasgow)

09:40-10:10 Coffee Break

SCIENTIFIC SESSION 4: Biomarkers, resistance and new targets
Chairs: Simona Soverini (Bologna)

10:10-10:25	**<u>Keynote Presentation</u>:** Whole genome sequencing reveals that the Philadelphia chromosome (Ph) can evolve and gain complex sequence rearrangements associated with tyrosine kinase inhibitor (TKI) resistance	Susan Branford (Adelaide)
10:25-10:30	*Discussion*	
	Selected Abstracts: *(12' + 3' discussion)*	
10:30-10:45	Partner Matters: the role of the 5' ABL fusion gene in asciminib efficacy	Elias Lagonik (Adelaide)
10:45-11:00	STAT5-targeting monobodies as therapeutic (add-on) option in chronic myeloid leukemia	Inga B. Leske (Marburg)
11:00-11:15	DNA methylation instability as a biomarker for response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia	Dennis Kim (Toronto)

11:15-11:30	The majority of BCR::ABL1 mutations associated with clinical resistance to asciminib retain asciminib binding affinity, alter kinase structure, activate kinase activity and confer cross-resistance to TGRX-678	Ariel Leyte-Vidal (San Francisco)
11:30-11:45	Establishing an iPSC-based platform to elucidate and overcome primary imatinib resistance in chronic myeloid leukaemia stem cells	John Joson Ng (Singapore)

11:45-13:40 Lunch and Poster Viewing

12:30-13:30 **CONCURRENT MEET-THE-EXPERT SESSIONS (pre-registration required)**
1. Frontline therapy – Andreas Hochhaus (Jena) and Massimo Breccia (Rome)
2. MPN – David Ross (Adelaide) and John Mascarenhas (New York)
3. Meet the editor – Jorge Cortes (Augusta) and Robert P. Gale (London)

SPECIAL LECTURE (4):
Chair: Sin Tiong Ong (Singapore)

13:40-14:00	ASXL1 mutation induces TKI resistance in CML cells through upregulation of ALOX5 expression	Takeshi Kondo (Sapporo)
14:00-14:05	*Discussion*	

SCIENTIFIC SESSION 5: New drugs and clinical trials
Chair: Fausto Castagnetti (Bologna)

14:05-14:20	**Keynote Presentation:** Targeting chronic myeloid leukemia with potent and specific BCR::ABL1 degraders	Michael Deininger (Ann Arbor)
14:20-14:25	*Discussion*	
	Selected Abstracts: *(12' + 3' discussion)*	
14:25-14:40	Efficacy and safety of asciminib in patients with chronic-phase chronic myeloid leukemia (CML-CP) after 1 tyrosine kinase inhibitor (TKI): Interim analysis (IA) of the phase 2 ASC2ESCALATE trial	Jorge Cortes (Augusta)
14:40-14:55	Olverembatinib (HQP1351) as second-line therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML)	Weiming Li (Wuhan)
14:55-15:10	First preliminary results of a multicenter randomized phase III study of vamotinib (PF-114) versus imatinib in Ph-positive chronic phase chronic myeloid leukemia patients	Ekaterina Chelysheva (Moscow)
15:10-15:25	Asciminib once or twice daily demonstrates high efficacy and favorable safety in pretreated patients with chronic myeloid leukemia and suboptimal response, resistance or intolerance: 96-week results	Carla Maria Boquimpani (Rio de Janeiro)

	from the ASC4OPT study	
15:25-15:40	Interim analysis of a multicentre study of patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukaemia (RODEO study)	Nienke Lokhorst (Nijmegen)

15:40-16:10 Coffee Break

16:10-16:20 **JOHN GOLDMAN PRIZE PRESENTATION**
Presenter: François Guilhot (Poitiers)
Awardee 2025: Delphine Rea (Paris)

JOHN GOLDMAN PRIZE: SPECIAL LECTURE (5)
Chair: François Guilhot (Poitiers)

16:20-16:40	On the road to better CML care: bridging research, biology, education and the clinic	Delphine Rea (Paris)
16:40-16:45	*Discussion*	

16:50-17:50 **Poster Session 2**
Poster leaders: Anna Eiring (El Paso), Emre Eşkazan (Istanbul), Hemant Malhotra (Jaipur)

Sunday, October 12, 2025

07:00-08:00 John Goldman charity Fun Run, organized by the iCMLf (Pre-registration required)

WORKSHOP FOR NON-CLINICAL SCIENTISTS #2: Clonal tracking, lineage tracing, and fate mapping over time
Chairs: Ravi Bhatia (Birmingham, USA), Daniela Krause (Mainz)

09:00-09:05	Introduction	
09:05-09:30	A track of the clones: new tools to study clonal evolution of blood stem cells	David Kent (York)
09:30-09:40	*Discussion*	
09:40-10:05	Targeted readout of DNA methylation states in single cells enables joint profiling of clonal identity and cell state	Michael Scherer (Heidelberg)
10:05-10:15	*Discussion*	
10:15-10:40	Family matters: clonal memory of cell division in blood progenitors	Alessandro Donada (Paris)
10:40-10:50	*Discussion*	
10:50-11:00	Conclusion	

SCIENTIFIC SESSION 6: CML special scenarios
Chair: Deborah White (Adelaide)

09:10-09:25	**Keynote Presentation:** The new ELN recommendations: what is in, what is out, what is different, what is not	Dragana Milojkovic (London)

09:25-09:30 *Discussion*

Selected Abstracts: *(12' + 3' discussion)*

09:30-09:45	Dynamics and outcomes of second-Line therapy in pediatric chronic myeloid leukemia: insights from the longitudinal German CML-paed II cohort	Stephanie Sembill (Erlangen)
09:45-10:00	Chronic myeloid leukemia (CML) treatment discontinuation after two-step dose reduction: First results of the Phase 2 HALF study	Daniela Žáčková (Brno)
10:00-10:15	Treatment-free remissions (TFR) in children with chronic myeloid leukemia (CML) -- Longer-term results from the Tata Memorial Hospital (TMH) pediatric CML(pCML) cohort	Nirmalya Roy Moulik (Mumbai)
10:15-10:30	Molecular response in pregnant chronic myeloid leukemia patients during interruptions of tyrosine kinase inhibitors therapy and impact of interferon on response preservation	Ekaterina Chelysheva (Moscow)

10:30-11:00 Coffee Break

SPECIAL LECTURE (6):
Chair: Jerald Radich (Seattle)

11:00-11:20	Advances in Natural Killer cell (NK) cancer therapy	Dan S. Kaufman (La Jolla)
11: 20-11:25	*Discussion*	

ESH INTERNATIONAL JOHN GOLDMAN RESEARCH AWARD CEREMONY 2025
Chair: Hervé Dombret (Paris)

11:25-11:30	Announcing the Awardee 2025	Hervé Dombret (Paris)
11:30-11:40	Single-cell precision medicine: early profiling of therapy effects in clinical decision-making	Stein-Erik Gullaksen (Bergen)
11:40-11:45	*Discussion*	
11:45-11:55	**iCMLf PRIZE PRESENTATION:** **Presenter:** Pier Paolo Piccaluga (Bologna) **Awardee 2025:** Nicholas A. Othieno-Abinya (Nairobi)	

iCMLf PRIZE: SPECIAL LECTURE (7)
Chair: Pier Paolo Piccaluga (Bologna)

11:55-12:15	Twenty years of managing chronic myeloid leukaemia in Kenya	Nicholas A. Othieno-Abinya (Nairobi)
12:15-12:20	*Discussion*	

12:20-12:25 Closing Remarks

MEETING CLOSURE